Showing 1531-1540 of 10214 results for "".
Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.A Definitive Guide to Recognizing and Treating “Maskne”
https://practicaldermatology.com/columns/clinical-focus-1/a-definitive-guide-to-recognizing-and-treating-maskne/23520/Practical Dermatology® magazine’s resident acne columnist offers step-by-step guidance.The Heritage of PDGF
https://practicaldermatology.com/topics/regenerative-medicine/the-heritage-of-pdgf/48868/From its discovery nearly half a century ago to its current place in patient care and scientific conversation in aesthetic medicine, poorly healing skin wounds, orthopedics, and dental surgical reconstruction, platelet-derived growth factor (PDGF) stands as both a milestone of molecular biology andNon-genital Warts: A Review of Current Treatments
https://practicaldermatology.com/topics/general-topics/non-genital-warts-a-review-of-current-treatments/21884/When determining which treatment modality to choose for non-genital warts, there are several factors to consider, including the convenience of the treatment, patient discomfort, location of warts, and potential side effects.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyDo You Own Real Estate in Your Practice?
https://practicaldermatology.com/topics/practice-management/do-you-own-real-estate-in-your-practice/20783/Five tips for dermatologists considering the sale of real estate to REIT.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muMelanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.Navigating Industry: Tips for Successful Relationships and Partnerships
https://practicaldermatology.com/issues/january-february-2025/navigating-industry-tips-for-successful-relationships-and-partnerships/32976/Dermatology is no longer confined to the physician-patient interaction in a busy clinic, private practice office, or academic center.Advances in Topicals for Skin Conditions
https://practicaldermatology.com/topics/psoriasis/advances-in-topicals-for-skin-conditions/20197/There are more topicals available today than ever before for acne, rosacea, and psoriasis, and even more are coming down the pike. Larry Green, MD, reviews the current topical landscape in dermatology and previews what’s in the pipeline.